130-LB: Dapagliflozin and the Incidence of Type 2 Diabetes in Patients with Chronic Kidney Disease

The DAPA-CKD trial demonstrated a significant reduction in the risk of adverse kidney and cardiovascular outcomes participants with chronic disease (CKD), without type 2 diabetes (T2D), treated dapagliflozin 10 mg once daily compared to placebo (randomized 1:1). This pre-specified analysis explored effect on incident T2D cohort enrolled DAPA-CKD. A subgroup 1,398 CKD, no prior history diabetes, HbA1c <6.5% at baseline were included. In this exploratory analysis, surveillance for new-onset (confirmed ≥6.5%) was accomplished through periodic testing (part study protocol) comparison between treatment groups assessed Cox proportional hazards model. Over median follow-up 2.4 years, developed 33/701 (4.7%) group 21/697 (3.0%) group. corresponded event rates 2.4/100-patient years 1.5/100-patient respectively. Dapagliflozin led 38% incidence (hazard ratio [95%CI] 0.62 [0.36, 1.08]). There heterogeneity prevention based most key prespecified subgroups, including age, glycemic status, blood pressure, estimated glomerular filtration rate, albuminuria, race region, but more pronounced females (p interaction 0.03). More than 90% who had prediabetes (HbA1c 5.7-6.4%). meta-analysis DAPA-HF (dapagliflozin heart failure reduced ejection fraction) that 0.66 [0.51, 0.87]; p=0.003), studies 0.78). explorative patients new T2D, an consistent across DAPA-HF. Disclosure P. Rossing: Advisory Panel; Self; Astellas Pharma Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Gilead Sciences, Merck KGaA, Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Vifor Management Ltd. A. Langkilde: Employee; Stock/Shareholder; AstraZeneca. D. C. Wheeler: Consultant; GlaxoSmithKline plc., Janssen Global Services, LLC., Mundipharma International, Tricida, Speaker’s Bureau; Amgen BioPharma, Napp Pharmaceuticals, H. L. Heerspink: AbbVie Chinook, CSL Behring, Fresenius Medical Care, Research Development, LLC, Co., Mitsubishi Corporation Life Sciences Limited, Nordisk, Retrophin, Support; LLC. Dapa-ckd group: n/a. Vart: None. G. M. Chertow: Ardelyx, Baxter, Cricket Health, DURECT Corporation, Reata Other Relationship; Akebia Therapeutics, Vertex Pharmaceuticals Incorporated. F. Hou: N. Jongs: J. Mcmurray: Cytokinetics DalCor Novartis Servier Laboratories, Theracos, Inc. R. Correa-rotter: (Canada) Ltd., Takeda Pharmaceutical Co. B. Stefansson: Toto: Medscape Education, Otsuka America Pharmaceutical, Quest Diagnostics, Relypsa Funding AstraZeneca